InvestorsHub Logo
Followers 36
Posts 1468
Boards Moderated 0
Alias Born 11/12/2013

Re: DaubersUP post# 234175

Wednesday, 07/11/2018 7:50:44 PM

Wednesday, July 11, 2018 7:50:44 PM

Post# of 403039
I disagree with your comment:

... 99.7% of investors do not understand how strong that statement is.



Here's the statement you're referring to:

Leo Ehrlich, Chief Executive Officer of Cellceutix, commented: “We had always wanted to explore Prurisol’s clinical merit, as it had excellent results in laboratory studies. We put it to the test under some of the most demanding conditions, with respect to the IGA versus PASI scoring systems; short treatment duration; low dosing levels; enrollment that included patients who were previously treated with biologics; and evaluation in mild to moderate psoriasis patients, where it can be more difficult to achieve a meaningful therapeutic effect. To see such a strong response among patients, achieving clear to almost clear skin without serious side effects—the downside of biologics—in such a short period of time, is exceptional.



http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint

One would have to have the combined vision of Stevie Wonder, Jose Feliciano, and the late Ray Charles to miss the strength of Leo's statement, above in boldface.

Leo is alluding to a level of efficacy, minus AEs, that is unheard of in psoriatic drug development. I think we shareholders are in for a real treat.






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News